Literature DB >> 11112366

Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation.

I Sereti1, J Gea-Banacloche, M Y Kan, C W Hallahan, H C Lane.   

Abstract

Expression of the alpha chain of the interleukin 2 receptor on T lymphocytes is restricted, increasing in the setting of activation, particularly after antigenic stimulation via the TCR. The effects of IL-2 in vitro on the expression of CD25 and proliferation as well as the cytokine induction in CD25-depleted T cells were studied. CD25-depleted and PBMC of healthy donors were cultured for 7 days with 0, 10, or 100 IU/ml of IL-2. Phenotypic analysis and measurement of cytokines in the culture supernatants were performed. IL-2 led to a dose-dependent induction of the IL-2R alpha chain on both CD4 and CD8 T lymphocytes. In the CD25-depleted cultures, IL-2 treatment (100 IU/ml) increased the percentage of CD4 T cells expressing CD25 by 30.6% (P = 0.05) and of CD8 T cells by 48.2% (P = 0.01) on day 7 compared to no treatment. In the PBMC cultures the increase on day 7 was 36.4% for CD4 (P = 0.01) and 50.8% (P = 0.025) for CD8 T lymphocytes. The patterns of cytokine induction in the CD25-depleted and control cultures were similar with increases of IFN-gamma, GM-CSF, IL-16, TNF alpha, and soluble IL-2 receptor in the IL-2-containing cultures. CFSE experiments demonstrated the proliferative capacity of both CD25-positive and -negative T cells. Interleukin 2 alone can lead to a dose-dependent induction of the alpha chain of its receptor on resting CD4 and CD8 T lymphocytes. IL-2 as a sole stimulant is also associated with generation of a cytokine milieu that includes IFN-gamma, GM-CSF, IL-16, and TNF alpha. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112366     DOI: 10.1006/clim.2000.4929

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

1.  In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.

Authors:  Irini Sereti; Hiromi Imamichi; Ven Natarajan; Tomozumi Imamichi; Meena S Ramchandani; Yunden Badralmaa; Steve C Berg; Julia A Metcalf; Barbara K Hahn; Jean M Shen; April Powers; Richard T Davey; Joseph A Kovacs; Ethan M Shevach; H Clifford Lane
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

2.  An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.

Authors:  Yik Andy Yeung; Veena Krishnamoorthy; Danielle Dettling; Cesar Sommer; Kris Poulsen; Irene Ni; Amber Pham; Wei Chen; Sindy Liao-Chan; Kevin Lindquist; S Michael Chin; Allison Given Chunyk; Wenyue Hu; Barbra Sasu; Javier Chaparro-Riggers; Ivana Djuretic
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

3.  Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.

Authors:  Prabhakaran Kumar; Alejandra Marinelarena; Divya Raghunathan; Vandhana K Ragothaman; Shikha Saini; Palash Bhattacharya; Jilao Fan; Alan L Epstein; Ajay V Maker; Bellur S Prabhakar
Journal:  Cell Mol Immunol       Date:  2018-03-26       Impact factor: 11.530

4.  Differential Interleukin-2 Transcription Kinetics Render Mouse but Not Human T Cells Vulnerable to Splicing Inhibition Early after Activation.

Authors:  Debojit Bose; Alexander Neumann; Bernd Timmermann; Stefan Meinke; Florian Heyd
Journal:  Mol Cell Biol       Date:  2019-07-29       Impact factor: 4.272

5.  Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.

Authors:  R Cabrera; M Ararat; E A Eksioglu; M Cao; Y Xu; C Wasserfall; M A Atkinson; C Liu; D R Nelson
Journal:  Scand J Immunol       Date:  2010-10       Impact factor: 3.487

6.  IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3.

Authors:  Hiromi Imamichi; Irini Sereti; H Clifford Lane
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

7.  A role for cell-autocrine interleukin-2 in regulatory T-cell homeostasis.

Authors:  Amanpreet Singh Chawla; Jasneet Kaur Khalsa; Atika Dhar; Suman Gupta; Danish Umar; Gopalakrishnan Aneeshkumar Arimbasseri; Vineeta Bal; Anna George; Satyajit Rath
Journal:  Immunology       Date:  2020-04-14       Impact factor: 7.397

8.  IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.

Authors:  Jianmin Zhu; Jin-Qing Liu; Min Shi; Xinhua Cheng; Miao Ding; Jianchao C Zhang; Jonathan P Davis; Sanjay Varikuti; Abhay R Satoskar; Lanchun Lu; Xueliang Pan; Pan Zheng; Yang Liu; Xue-Feng Bai
Journal:  JCI Insight       Date:  2018-04-05

9.  In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients.

Authors:  Laurence Weiss; Fabrice A Letimier; Matthieu Carriere; Sylvie Maiella; Vladimira Donkova-Petrini; Brice Targat; Arndt Benecke; Lars Rogge; Yves Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

10.  Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta.

Authors:  Anja Scholzen; Diana Mittag; Stephen J Rogerson; Brian M Cooke; Magdalena Plebanski
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.